Literature DB >> 6859262

Presence in normal human urine of a hypotensive and platelet-activating phospholipid.

M Sánchez-Crespo, P Iñarrea, V Alvarez, F Alonso, J Egido, L Hernando.   

Abstract

Urine from normotensive volunteers and patients with systemic lupus erythematosus glomerulonephropathy was sequentially concentrated by negative-pressure ultrafiltration, dialyzed against distilled water, and extracted into the chloroform phase of a mixture of organic solvents(chloroform:methanol:water, 1:1:0.9 vol/vol). The lipid fraction was further purified by thin-layer chromatography on silica gel plates using neutral, acidic, and basic mixtures of organic solvents and it was then tested for its ability to induce the release of [3H]serotonin from rabbit platelets. All of the samples contained a platelet-activating moiety similar to a synthetic platelet-activating factor (PAF-acether) on the basis of its chromatographic behavior, resistance to the pretreatment of platelets by 10(-6) M indomethacin, and loss of activity by alkaline methanolysis or treatment by phospholipases A2, C, and D. Cross-densensitization experiments between synthetic PAF-acether and the urine factor showed that both compounds act on platelets through the activation of the same putative receptor. Further, the urine factor induced hypotension when intra-arterially injected in normotensive rats, and this activity was also abrogated by alkaline methanolysis. In summary, these data provide evidence of the presence in normal human urine and, probably, of the release by the kidney of a lipid factor with platelet-activating and hypotensive activity whose general structure seems to be alkyl-acyl-glyceryl-phosphorylcholine and, therefore, is similar to the structure of the inflammatory mediator PAF-acether and the antihypertensive polar renomedullary lipid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6859262     DOI: 10.1152/ajprenal.1983.244.6.F706

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  IgA immune aggregates stimulate platelet-activating factor and superoxide anion production by human neutrophils. A comparison with IgG aggregates.

Authors:  P Hernando; J Egido; R de Nicolas; E Gonzalez
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  PAF of biological fluids in disease: IV. Levels in blood in allergic reactions induced by drugs.

Authors:  M Lazanas; C A Demopoulos; S Tournis; S Koussissis; K Labrakis-Lazanas; X Tsarouhas
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

Authors:  F Lopez Diez; M L Nieto; S Fernandez-Gallardo; M A Gijon; M Sanchez Crespo
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

4.  Fibronectin (FN) decreases glomerular lesions and synthesis of tumour necrosis factor-alpha (TNF-alpha), platelet-activating factor (PAF) and FN in proliferative glomerulonephritis.

Authors:  A Ortíz; J Alonso; M Gómez-Chiarri; J L Lerma; D Seron; E Condom; E González; J Egido
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

6.  Measurement of platelet-activating factor in human blood by high performance thin layer chromatography and its clinical application.

Authors:  H P Li; R X Zhang
Journal:  J Tongji Med Univ       Date:  1993

7.  Cyclosporin A (CsA) modulates the glomerular production of inflammatory mediators and proteoglycans in experimental nephrosis.

Authors:  C Bustos; S González-Cuadrado; M Ruiz-Ortega; C Gómez-Guerrero; E González; J J Plaza; J Egido
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 8.  The potential pathophysiological role of platelet-activating factor in human diseases.

Authors:  C Kroegel
Journal:  Klin Wochenschr       Date:  1988-05-02

9.  Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits.

Authors:  P Zarco; C Maestre; G Herrero-Beaumont; E González; R Garcia-Hoyo; F J Navarro; P Braquet; J Egido
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

10.  Presence of platelet-activating factor in pyuria in humans.

Authors:  I Ikeda; M Oda; M Sakakura; K Yasunaga
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.